Results 61 to 70 of about 45,696 (262)

Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization [PDF]

, 2020
Objectives: The aim of this study was to evaluate the incidence of ceftazidime/avibactam resistance among Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae (KPC-Kp) strains isolated from patients with bloodstream infection.
Ambretti S., Viale P. L., Gaibani P., Campoli C., Re M. C.   +4 more
core   +1 more source

Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug-resistant Enterobacterales from United States Medical Centers (2018-2022).

Diagnostic microbiology and infectious disease, 2023
A total of 35,360 Enterobacterales isolates were consecutively collected from 75 US medical centers in 2018-2022. Among these isolates, 2612 (7.4%) were categorized as multidrug-resistant (MDR).
H. Sader, R. Mendes, Leonard R. Duncan, J. Kimbrough, C. Carvalhaes, M. Castanheira   +5 more
semanticscholar   +1 more source

Outbreak of Klebsiella pneumoniae ST11 Resistant To Ceftazidime-Avibactam Producing KPC-31 and the Novel Variant KPC-115 during COVID-19 Pandemic in Argentina

Microbiology Spectrum, 2022
We describe an outbreak of Klebsiella pneumoniae sequence type 11 (ST11) producing KPC variants resistant to ceftazidime-avibactam. Six patients hospitalized in the intensive care unit (mostly due to critical COVID pneumonia) presented infection or ...
Federico Nicola, Daniela Cejas, Francisco González-Espinosa, Silvia Relloso, Fabián Herrera, Pablo Bonvehí, Jorgelina Smayevsky, Roque Figueroa-Espinosa, Gabriel Gutkind, Marcela Radice   +9 more
doaj   +1 more source

Multicenter Evaluation of an MIC-Based Aztreonam and Ceftazidime-Avibactam Broth Disk Elution Test

Journal of Clinical Microbiology, 2023
Due to limited therapeutic options, there is a clinical need to assess the in vitro activity of the combination of aztreonam (ATM) and ceftazidime-avibactam (CZA) to guide the therapeutic management of multidrug-resistant (MDR) Gram-negative organism ...
Harley Harris, L. Tao, E. Jacobs, Y. Bergman, Ayomikun Adebayo, T. Tekle, Shawna Lewis, Ashley Dahlquist, Taylor C. Abbey, E. Wenzler, R. Humphries, P. Simner   +11 more
semanticscholar   +1 more source

Use of Ceftazidime-Avibactam for Suspected or Confirmed Carbapenem-Resistant Organisms in Children: A Retrospective Study

, 2023
Haiyang Meng,1,2 Yongmei Zhao,1,2 Qi An,1,2 Baoling Zhu,3 Zhe Cao,4 Jingli Lu1,2 1Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People’s Republic of China; 2Henan Key Laboratory of Precision Clinical Pharmacy ...
An Q, Cao Z, Lu J, Zhu B, Meng H, Zhao Y
core  

The discovery of ceftazidime/avibactam as an anti-Mycobacterium avium agent [PDF]

Journal of Antimicrobial Chemotherapy, 2017
To determine if ceftaroline and ceftazidime combined with avibactam are efficacious against pulmonary Mycobacterium avium complex (MAC) disease.First, we performed a concentration-effect study of ceftaroline and ceftaroline/avibactam against extracellular MAC in test tubes.
Devyani, Deshpande, Shashikant, Srivastava, Moti L, Chapagain, Pooi S, Lee, Kayle N, Cirrincione, Jotam G, Pasipanodya, Tawanda, Gumbo   +6 more
openaire   +2 more sources

In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment [PDF]

, 2018
Objectives: KPC-producing Klebsiella pneumoniae (KPC-Kp) represent a serious problem worldwide. Herein, we describe the evolution of ceftazidime/avibactam resistance by sequencing longitudinal clinical isolates from a patient with KPC-Kp bloodstream ...
Andrea Berlingeri, Sara Tedeschi, Paolo Gaibani, Giannella, Maddalena, Maddalena Giannella, Silvia Lidia Volpe, Tedeschi, Sara, Bartoletti, Michele, Erika Scaltriti, Berlingeri, Andrea, Lewis, Russell E., Michele Bartoletti, Caterina Campoli, Simone Ambretti, Gaibani, Paolo, Scaltriti, Erika, Campoli, Caterina, Francesco Cristini, Pongolini, Stefano, Volpe, Silvia Lidia, Cristini, Francesco, Ambretti, Simone, Stefano Pongolini, Russell E Lewis   +23 more
core   +1 more source

Identification of a Novel Ceftazidime-Avibactam-Resistant KPC-2 Variant, KPC-123, in Citrobacter koseri Following Ceftazidime-Avibactam Treatment

Frontiers in Microbiology, 2022
This study reported the identification of a novel ceftazidime-avibactam-resistant KPC-2 variant, KPC-123, in a Citrobacter koseri isolated from a patient in a Chinese hospital following ceftazidime-avibactam treatment of infection caused by OXA-232-producing Klebsiella pneumoniae.
Lin Wang, Weiyi Shen, Rong Zhang, Jiachang Cai   +3 more
openaire   +3 more sources

Ceftazidime/avibactam versus polymyxin B in carbapenem-resistant Klebsiella pneumoniae infections: a propensity score-matched multicenter real-world study

Infection
In this retrospective observational multicenter study, we aimed to assess efficacy and mortality between ceftazidime/avibactam (CAZ/AVI) or polymyxin B (PMB)-based regimens for the treatment of Carbapenem-resistant Klebsiella pneumoniae (CRKP) infections,
Haiwen Zhuang, Qiang Qu, Wen Long, Qin Hu, Xiao-li Wu, Ying Chen, Qing Wan, Tian-Tian Xu, Yue Luo, Hailing Yuan, Qiong Lu, Jian Qu   +11 more
semanticscholar   +1 more source

Impact of a Rapid Molecular Test for Klebsiella pneumoniae Carbapenemase and Ceftazidime-Avibactam Use on Outcomes after Bacteremia Caused by Carbapenem-Resistant Enterobacterales.

Clinical Infectious Diseases, 2022
BACKGROUND Patients with bacteremia due to carbapenem-resistant Enterobacterales (CRE) experience delays until appropriate therapy and high mortality rates.
M. Satlin, Liang Chen, A. Gomez-Simmonds, Jamie Marino, G. Weston, T. Bhowmick, S. Seo, S. Sperber, A. Kim, Brandon Eilertson, Sierra Derti, S. Jenkins, M. Levi, M. Weinstein, Yi-Wei Tang, T. Hong, S. Juretschko, K. Hoffman, T. Walsh, L. Westblade, A. Uhlemann, Barry N. Kreiswirth   +21 more
semanticscholar   +1 more source